Vimal Elaichi ad row: Delhi High Court reserves order on notices to Shah Rukh Khan, Ajay DevgnThe Delhi High Court has reserved its decision on a legal challenge regarding show-cause notices issued to Bollywood actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff by the Maharashtra Food and Drug Administration (FDA). The notices allege that the actors' advertisements for Vimal Elaichi constitute 'surrogate advertising' for Vimal pan masala, a product banned in Maharashtra. PB Agro LLP, the master licensee for the Vimal brand, filed the plea, arguing that the notices unfairly target the brand ambassadors rather than the company itself and claim they do not promote pan masala. The company asserts compliance with laws prohibiting pan masala in Maharashtra and denies engaging in surrogate advertising. The case involves a dispute over jurisdiction between Delhi and Maharashtra.
Bias read (Center): The article presents both sides of the legal dispute without overtly favoring one party. It includes statements from PB Agro LLP and the opposing counsel, providing balanced perspectives on the jurisdictional issue and claims of surrogate advertising. There is no evident editorializing or biased phr
Why factuality (95): This article closely mirrors the primary source document, detailing the show-cause notices, the allegations of surrogate advertising, and the company's arguments regarding compliance and jurisdiction. It includes specific dates and legal references, enhancing its factual accuracy.
Why objectivity (90): The article maintains a balanced tone, presenting the facts without apparent bias. The judicial process and legal arguments are described objectively, without emotional language or editorializing.
Scroll.inIndependentCenterFactual 90Objective 859/8/2026Vimal Elaichi, a mouth freshener brand, has approached the Delhi High Court challenging show-cause notices issued by the Maharashtra Food and Drug Administration (FDA). The notices were directed at brand ambassadors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, accusing them of promoting Vimal Pan Masala, a banned product. The FDA claimed the advertisement constituted surrogate promotion and demanded proof that Vimal Elaichi is independently available for sale. The company argues that the FDA's actions unfairly target the celebrities without addressing the company directly, and that the allegations are unfounded as Vimal Pan Masala has not been sold in Maharashtra since 2001. The court has yet to determine if it has jurisdiction over the case. The Union government's counsel suggested the petition should have been filed in the Bombay High Court.
Bias read (Center): The article presents the legal dispute between a private company and a state regulatory body without overtly favoring either side. While the issue involves government regulation and corporate interests, the reporting remains balanced, focusing on the legal arguments rather than taking a clear stance
Why factuality (90): The article accurately reflects the primary source information, including the show-cause notices, the nature of the alleged surrogate advertising, and the company's defense. It mentions the historical context of the ban on pan masala, adding depth to the factual background.
Why objectivity (85): While the article presents the facts clearly, there is a subtle emphasis on the company's argument that the FDA's actions were unjustified. This may lean slightly towards supporting the company's position, though not overtly biased.
NDTVParty-alignedCenterFactual: no official source document/info detectedObjective 809/8/2026The makers of Vimal Elaichi, a cardamom product, have approached the Delhi High Court against notices issued by the Food Safety and Standards Authority of India (FSSAI) to three actors involved in their advertising campaigns. PB Agro, the company behind the brand, claims they work with well-known actors to promote their product and asserts that their advertisement campaigns comply fully with applicable laws.
Bias read (Center): The article presents a factual account of a legal action taken by a company against regulatory notices without any evident ideological framing or biased language. It does not take a stance on the legality or validity of the FSSAI notices nor does it favor either the company or the regulatory body.
Why factuality: no official source document/info detected
Why objectivity (80): The tone remains neutral, presenting both sides of the issue without overt bias. However, there is slight emphasis on the company's perspective, which could be seen as slightly more favorable.
India
